ClinicalTrials.gg
Status unknownNCT06595797Updated Sep 19, 2024

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome

A Phase 2 interventional study of HRS9531 and HRS9531placebo in Obese Subjects With Polycystic Ovary Syndrome (PCOS), sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Status unknown. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2024), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Randomized, double-blind, placebo-controlled study of HRS9531 in PCOS subjects

02

Conditions studied

  • Obese Subjects With Polycystic Ovary Syndrome (PCOS)
03

In context

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

This study's planned enrollment of 144 is above the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.

Browse Polycystic Ovary Syndrome studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. With my consent and signed , I am willing and able to complete this study in accordance with the requirements of the experimental protocol
  2. Women aged 18-40 (including the threshold) on the date of signing the informed consent;
  3. Patients who meet the diagnostic criteria for polycystic ovary syndrome;
  4. (BMI) ≥28 kg/m2;
  5. Have controlled diet and exercise for at least 3 months, and the weight change is less than 5 kg
  6. Within 2 months from the signing of the informed consent to the last drug use, there is no family planning and consent to take trial-approved measures, and there is no egg donation plan

Exclusion criteria

Exclusion Criteria:

  1. Endometrial is necessary as assessed by the investigators, and the pathology of the endometrial biopsy indicates significant abnormalities
  2. 12-lead (ECG) results showing abnormalities that may affect the safety of the subject, including but not limited to myocardial infarction, severe arrhythmias (e.g., supraventricular tachycardia, atrial fibrillation, atrial flutter, degree II or III atrioventricular block, etc.), and > 470 ms
  3. Poor blood pressure control (with or without antihypertensive therapy) : systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening
  4. PHQ-9 score ≥15 points
  5. The presence of endocrine disorders or medical history that may significantly affect body weight
  6. Presence of other medical conditions or history that may cause hyperandrostenia or irregular menstruation
  7. Presence of a history of gynecological conditions that may affect the evaluation of menstruation (including, but not limited to, history of hysterectomy, vaginal atresia, uterine adhesions)
  8. Abnormal uterine bleeding for reasons other than PCOS or unexplained abnormal uterine bleeding occurred within 6 months
  9. Endometrium-related surgery within 1 year indicated significant pathological abnormalities of endometrial tissue, and safety risks were assessed by researchers
  10. History of pregnancy, miscarriage, childbirth or breastfeeding within 6 months
  11. Have any disease or history that affects gastric empty. such as gastric bypass surgery, pyloric stenosis, etc., long-term use of drugs that directly affect gastrointestinal motility, serious gastrointestinal disease (such as active peptic ulcer, inflammatory bowel disease, etc.), or have undergone gastrointestinal surgery (except surgery that has no significant effect on gastrointestinal motility), Such as gastrointestinal polypectomy, appendectomy and hemorrhoid surgery);
  12. A history or disease of acute or chronic pancreatitis or pancreatic injury; Patients with a history of acute cholecystitis or symptomatic/treatable gallbladder disease (except those who had previously undergone cholecystectomy and were deemed eligible by the investigator to be enrolled);
  13. History or family history of medullary thyroid carcinoma (MTC) or multiple endocrine adenomatosis type 2 (MEN2);
  14. Severe infection, severe trauma, or major or major surgery in the previous 6 months
  15. A history of severe cardiovascular and cerebrovascular disease, including decompensated heart failure ( ratings III and IV), unstable angina pectoris, stroke or , myocardial infarction, severe arrhythmia, or coronary bypass grafting or percutaneous coronary intervention within the previous 6 months;
  16. Any organ-system within the previous 5 years, regardless of evidence of local recurrence or , except cured local basal cell carcinoma of the skin, cervical carcinoma in situ, and prostate carcinoma in situ;
  17. Present or suspected depression, anxiety disorder, bipolar disorder, suicidal tendencies, schizophrenia, or other more serious mental illness
  18. A known or suspected history of alcohol and/or drug abuse or drug use
  19. A history of acute or chronic hepatitis, or other serious liver disease other than alcoholic fatty liver disease;
  20. A history of unstable or rapidly progressing kidney disease or end-stage kidney disease
  21. disease is present and systemic therapy or therapy is planned for the study period;
  22. Participated in a clinical trial of any drug or medical device within the previous 3 months, defined as signing and using the drug (including placebo) or the investigational medical device; Or is still in the trial drug within 5 half-lives (whichever is older);
  23. Those who have donated blood or lost blood ≥400 mL in the previous 3 months, or received blood transfusion
  24. Surgery is planned during the trial period (except for minor surgery that the investigator believes will not affect the trial);
  25. Mentally incapacitated or speech-impaired subjects are unable to fully understand or participate in the test process;
  26. Researchers and relevant staff of the research Centre or others directly involved in the implementation of the programme, as well as members of their immediate family (e.g. spouse, legal partner, parents, children or siblings); Hengrui company staff;
  27. There are circumstances (medical, psychological, social or geographical factors, etc.) that, in the investigator's judgment, affect the subject's safety or any other conditions that interfere with the evaluation of the test results.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Treatment group 1

    Drug: HRS9531 · Drug: HRS9531placebo

  • Experimental
    Treatment group 2

    Drug: HRS9531 · Drug: HRS9531placebo

  • Experimental
    Treatment group 3

    Drug: HRS9531 · Drug: HRS9531placebo

Interventions

  • HRS9531

  • DrugHRS9531placebo

    HRS9531placebo

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline at 32 weeks of treatment

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

Secondary outcomes

  1. Proportion of subjects with regular menstruation at 32 weeks of treatment

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

  2. Change in spontaneous menstrual frequency ratio from baseline at 32 weeks of treatment

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

  3. Proportion of subjects who ovulated regularly after 32 weeks of treatment

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

  4. Proportion of subjects with weight loss of ≥5%, ≥10%, ≥15%, ≥20% from baseline at 32 weeks of treatment

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

  5. BMI changes relative to baseline after 32 weeks of administration;

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

  6. Changes in waist circumference (WC) from baseline after 32 weeks of administration

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

  7. Proportion of subjects with at least 3 menstrual cycles of 21-35 days after 12-32 weeks of treatment;

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

  8. Changes in total testosterone (TT)from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  9. Changes in sex hormone binding globulin (SHBG)from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  10. Changes in free testosterone index (FAI),from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  11. Changes in anti-Miller tube hormone (AMH),from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  12. Changes in follicle stimulating hormone (FSH),from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  13. Changes in luteinizing hormone (LH)from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  14. Changes in LH/FSH;from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  15. Changes in fasting plasma glucose (FPG)from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  16. Changes in fasting serum insulin (FINS),from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  17. Changes in insulin resistance index (HOMA-IR)from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  18. Changes in triglycerides from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  19. Changes in total cholesterol (TC),from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  20. Changes in, low density lipoprotein cholesterol (LDL-C)from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  21. Changes in high density lipoprotein cholesterol (HDL-C)from baseline after 32 weeks of administration

    Time frame: 0week, 12week, 24week, 32week

  22. Changes in blood pressure from baseline

    Time frame: 0week, 4week,12week, 24week, 32week

  23. Adverse events,

    Time frame: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Dec 2025, 15 months later.

Of 23 phase 2 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Sep 19, 2024
StartEst.
Sep 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06595797
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 2024 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Shuang Li
Contact
Shuang.li.sl100@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion